Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 1/20 | 0.48 |
| ▸ | AR | P10275 | 2/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.42 |
| ▸ | TNK1 | Q13470 | 1/20 | 0.42 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.41 |
| ▸ | SMO | Q99835 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | PGK1 | P00558 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25597297 | 0.84 | AR (0.62) | ARCNR1CNR2CYP1A2PARP1 | |
| SCHEMBL25258747 | 0.79 | AR (0.47) | ARCNR1CNR2PARP1TNK2 | |
| SCHEMBL30510122 | 0.79 | AR (0.47) | ARCNR1CNR2PARP1TNK2 | |
| SCHEMBL1399326 | 0.77 | CYP1A2 (0.56) | HTR3ACNR1CNR2CYP1A2ALOX15 | |
| SCHEMBL29514489 | 0.77 | CYP1A2 (0.56) | HTR3ACNR1CNR2CYP1A2ALOX15 | |
| SCHEMBL17222798 | 0.76 | HTR3A (0.51) | HTR3ACYP1A2ALOX15CYP2C19HRH4 | |
| SCHEMBL26662252 | 0.76 | HTR3A (0.51) | HTR3ACYP1A2ALOX15CYP2C19HRH4 | |
| SCHEMBL30217816 | 0.76 | HTR3A (0.51) | HTR3ACYP1A2ALOX15CYP2C19HRH4 | |
| SCHEMBL28576085 | 0.76 | NR1H2 (0.54) | — | |
| SCHEMBL17222797 | 0.74 | HTR3A (0.49) | HTR3ACYP1A2ALOX15CYP2C19HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2822656-B1 | 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE | CANCER RES INST ROYAL (GB) | 2016-10-19 | — | — | EP | disclosed |
| US-9193689-B2 | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2015-11-24 | — | — | US | disclosed |
| US-20150099732-A1 | 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099732-A1 | 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE | TNKS, TNKS2, PARP11 | HTR3A 951/4885AR 850/4885PPARG 2012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.